Pradaxa Litigation Information
Pradaxa is a drug that is frequently prescribed to prevent strokes and atrial fibrillation or irregular heartbeat. Pradaxa has been linked to a significant number of deaths worldwide. It has also been linked to internal bleeding that can be severe and life-threatening in nature. Since Pradaxa is likely to be prescribed to elderly patients, the deaths and serious side effects have affected older people in disproportionate numbers.
Pradaxa (generic dabigatran), was approved in 2010 by the FDA to prevent atrial fibrillation that can lead to strokes. It was created by Boehringer Ingelheim Pharmaceuticals Inc. and has been prescribed by physicians throughout the world.
Pradaxa is a direct thrombin inhibitor, which means that it thins the blood by targeting its enzymes. When a patient has atrial fibrillation, his or her heart does not beat in a normal rhythm, causing blood clots to form around the heart. These clots can travel to other areas of the body and induce a stroke. Patients who already have atrial fibrillation are at an increased risk for stroke due to the formation of blood clots that may reach the brain.
If you or a loved one has experienced death or severe bleeding resulting in hospitalization for more than a day due to the use of Pradaxa, please contact us for an immediate and no cost case evaluation. One of our experienced attorneys will review your case and advise you of your legal options. Our attorneys have substantial experience in pharamaceutical injury claims and can help you to understand your legal options.